Back to Search Start Over

The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients.

Authors :
Torre, Matthew
Wen, Patrick Y
Iorgulescu, J Bryan
Source :
Neuro-Oncology Practice. Apr2023, Vol. 10 Issue 2, p126-131. 6p.
Publication Year :
2023

Abstract

Background Glioblastoma patients with hypermethylation of the O6-methylguanine-methyltransferase (MGMT) gene promoter have significantly improved survival when treated with temozolomide compared to patients with unmethylation of the MGMT promoter. However, the prognostic and predictive significance of partial MGMT promoter methylation is unclear. Methods The National Cancer Database was queried for patients newly diagnosed in 2018 with histopathologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma. The overall survival (OS) associated with MGMT promoter methylation status was assessed using multivariable Cox regression with Bonferroni correction for multiple testing (P <.008 was significant). Results Three thousand eight hundred twenty-five newly diagnosed IDH-wildtype glioblastoma patients were identified. The MGMT promoter was unmethylated in 58.7% (n = 2245), partially methylated in 4.8% (n = 183), hypermethylated in 3.5% (n = 133), and methylated not otherwise specified (NOS; likely consisting predominantly of hypermethylated cases) in 33.0% (n = 1264) of cases. Among patients that received first-line single-agent chemotherapy (ie likely temozolomide), compared to partial methylation (referent), MGMT promoter unmethylation was associated with worse OS (hazard ratio [HR] 1.94; 95% confidence interval [95 CI]: 1.54–2.44; P <.001) in multivariable Cox regression adjusted for major prognostic confounders. In contrast, a significant OS difference was not observed between partially methylated promoters and either hypermethylated (HR 1.02; 95 CI: 0.72–1.46; P =.90) or methylated NOS (HR 0.99; 95 CI: 0.78–1.26; P =.93) promoters. Among IDH-wildtype glioblastoma patients who did not receive first-line chemotherapy, MGMT promoter methylation status was not associated with significant differences in OS (P = 0.39–0.83). Conclusions Compared to MGMT promoter unmethylation, partial methylation was predictive of improved OS among IDH-wildtype glioblastoma patients treated with first-line single-agent chemotherapy—supporting the use of temozolomide therapy in these patients. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
20542577
Volume :
10
Issue :
2
Database :
Academic Search Index
Journal :
Neuro-Oncology Practice
Publication Type :
Academic Journal
Accession number :
162697240
Full Text :
https://doi.org/10.1093/nop/npac070